Sentinel node biopsy in thin and thick melanoma

Annals of Surgical Oncology

Volumn 20, Issue 8, 2013, Pages 2780-2786

  Mozzillo, Nicola ^a   Pennacchioli, Elisabetta ^b   Gandini, Sara ^b   Caracò, Corrado ^a   Crispo, Anna ^a   Botti, Gerardo ^a   Lastoria, Secondo ^a   Barberis, Massimo ^b   Verrecchia, Francesco ^b   Testori, Alessandro ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBINTERFERON ALPHA2B;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CLINICAL DECISION MAKING; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MELANOMA; MITOSIS; OVERALL SURVIVAL; PRIMARY TUMOR; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY; SENTINEL LYMPH NODE METASTASIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; MITOTIC INDEX; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

EID: 84880271555     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2826-0     Document Type: Article

References (47)

1. Wright BE, Scheri RP, Ye X, et al. Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg. 2008;143:892-899.
2. Vermeeren L, Van der Ent F, Sastrowijoto P, et al. Sentinel lymph node biopsy in patients with thin melanoma: occurrence of nodal metastases and its prognostic value. Eur J Dermatol. 2010; 20:30-34.
3. Warycha MA, Zakrzewski J, Ni Q, et al. Meta-analysis of sentinel lymph node positivity in thin melanoma (< or =1 mm). Cancer. 2009;115:869-879.
4. Ranieri JM, Wagner JD, Wenck S, et al. The prognostic importance of sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol. 2006;13:927-932.
5. Sekula-Gibbs SA, Shearer MA. Sentinel node biopsy should be offered in thin melanoma with mitotic rate greater than one. Dermatol Surg. 2011;37:1080-1088.
6. Balch CM. Surgical management of regional lymph nodes in cutaneous melanoma. J Am Acad Dermatol. 1980;3:511-24.
7. Balch CM, Soong SJ, Milton G, et al. A comparison of prognostic factors and surgical results of prognostic factors and surgical results in 1786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg. 1982; 196:677-84.
8. Perrot RE, Glass LF, Reitngen DS, et al. Reassessing the role of lymphatic mapping and sentinel lymphadenectomy in the management of cutaneous malignant melanoma. J Am Acad Dermatol 2003;49:567-88.
9. Reintgen D, Cruse CW, Wells K, et al. The orderly progression of melanoma nodal metastases. Ann Surg. 1994;220:759-767.
10. Gajdos C, Griffith KA, Wong SL, et al. Is there a benefit to sentinel lymph node biopsy in patients T4 melanoma? Cancer. 2009;115:5752-60.
11. Kim S, Garcia C, Rodriguez J, Coit D. Prognosis of thick cutaneous melanoma. J Am Coll Surg. 1999;188:241-7.
12. Caracò C, Celentano E, Lastoria S, et al. Sentinel lymph node biopsy does not change melanoma specific survival among patients with Breslow thickness greater than four millimetres. Ann Surg Oncol. 2004;11:198-202.
13. Kesmodel SB, Karakousis GC, Botbyl JD, et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol. 2005;12:449-458.
14. Cecchi R, Buralli L, Innocenti S, et al. Sentinel lymph node biopsy in patients with thin melanomas. J Dermatol. 2007;34:512-515.
15. Hershko DD, Robb BW, Lowy AM, et al. Sentinel lymph node biopsy in thin melanoma patients. J Surg Oncol. 2006;93:279-285.
16. Wright BE, Scheri RP, Ye X, et al. Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg. 2008;143:892-899; discussion 899-900.
17. Lowe JB, Hurst E, Moley JF, et al. Sentinel lymph node biopsy in patients with thin melanoma. Arch Dermatol. 2003;139:617-621.
18. Oliveira Filho RS, Ferreira LM, Biasi LJ, et al. Vertical growth phase and positive sentinel node in thin melanoma. Braz J Med Biol Res. 2003;36:347-350.
19. Olah J, Gyulai R, Korom I, et al. Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas. Br J Dermatol. 2003;149:662-663.
20. Kaur C, Thomas RJ, Desai N, et al. The correlation of regression in primary melanoma with sentinel lymph node status. J Clin Pathol. 2008;61:297-300.
21. Jacobs IA, Chang CK, DasGupta TK, et al. Role of sentinel lymph node biopsy in patients with thin (<1 mm) primary melanoma. Ann Surg Oncol. 2003;10:558-561.
22. Stitzenberg KB, Groben PA, Stern SL, et al. Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or =1.0 mm). Ann Surg Oncol. 2004;11:900-906.
23. Wong SL, Brady MS, Busam KJ, et al. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol. 2006;13:302-309.
24. Gimotty PA, Van Belle P, Elder DE, et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol. 2005;23:8048-8056.
25. Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer. 2003;97:1488-1498.
26. Francken AB, Shaw HM, Thompson JF, et al. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol. 2004;11:426-433.
27. McKinnon JG, Yu XQ, McCarthy WH, et al. Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer. 2003;98:1223-1231.
28. Gimotty PA, Guerry D, Ming ME, et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol. 2004;22:3668-3676.
29. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-6206.
30. Vermeeren L, van der Ent FW, Sastrowijoto PS, et al. Thick melanoma: prognostic value of positive sentinel nodes. World J Surg. 2009;33:2464-8.
31. Scoggins CR, Bowen AL, Martin II RC, et al. Prognostic information from sentinel lymph node biopsy in patients with thick melanoma. Arch Surg. 2010;145:622-627.
32. Ferrone CR, Panageas KS, Busam KJ, et al. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol. 2002;9:637-645.
33. Gershenwald JE, Mansfield PF, Lee JE, et al. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick primary melanoma. Ann Surg Oncol. 2000;7:160-165.
34. Carlson GW, Murray DR, Hestley A, et al. Sentinel Lymph node mapping for thick melanoma: should we be doing it? Ann Surg Oncol. 2003;10:408-415.
35. Gutzmer R, Satzger I, Thom KM, et al. Sentinel Lymph node status is the most important prognostic factor for thick melanomas. J Dtsch Dermatol Ges. 2008;6:198-203.
36. Gimotty PA, Elder DE, Fraker DL, et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol. 2007;25:1129-1134.
37. Jacobs IA, Chang CK, Salti G. Role of sentinel lymph node biopsy in patients with thick (>4 mm) primary melanoma. Am Surg. 2004;70:59-62.
38. Cherpelis BS, Haddad F, Messina J, et al. Sentinel lymph node micrometastases and other biological factors that predict outcome in patients with thicker melanomas. J Am Arch Dertatol. 2001;44:762-766.
39. Essner R, Chung MH, Bleicher R, et al. Prognostic implications of thick melanoma in the era of intraoperative lymphatic mapping and sentinel lymphadenectomy. Ann Surg Oncol. 2002;9:754-761.
40. Thompson JF, Shaw HM. The prognosis of patients with thick primary melanomas: is regional lymph node status relevant, and does removing positive regional nodes influence outcome? Ann Surg Oncol. 2002;9:719-722.
41. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-17.
42. Jakub JW, Huebner M, Shivers S, et al. The number of lymph nodes involved in metastatic disease does not affect outcome in melanoma patients as long as all disease is confined to the sentinel node. Ann Surg Oncol. 2002;16:224-51.
43. Eggermont AMM. Advances in systemic treatment of melanoma. Ann Oncol. 2010; 21:S733.
44. Garbe C, Eigentler TK, Keiholz U, et al. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist. 2011;16:5-24.
45. Ross MI. Sentinel node biopsy for melanoma. An update after two decades of experience. Semin Cutan Med Surg. 2010;29:238-248.
46. Ellis MC, Weerasinghe R, Corless CL, et al. Sentinel lymph node staging of cutaneous melanoma: predictors and outcome. Am Surg. 2010;199:663-668.
47. Hwu P. Treating cancer by targeting the immune system. N Engl J Med. 2010;363:779-781.